XJPX
4461
Market cap688mUSD
Jul 10, Last price
10,810.00JPY
1D
2.56%
1Q
24.97%
Jan 2017
481.18%
Name
DKS Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Kyoto, Japan, DKS Co. Ltd. is a global producer and purveyor of a diverse range of industrial chemicals and surfactants, serving numerous industries worldwide. The company’s operations are organized into six distinct segments: Surfactants, Amenity Materials, Polyurethane Materials, Functional Materials, Electronic Device Materials, and Life Sciences. Within its Surfactants division, DKS develops various types such as nonionic, anionic, cationic, polymerizable, and amphoteric compounds, in addition to specialized surfactant blends. The Amenity Materials segment features products like sucrose fatty acid esters, sodium carboxymethyl celluloses, cellulose nanofibers and other polymers, polyvinyl pyrrolidone, polyacrylamide and polyacrylate, and industrial deodorizers. Its Polyurethane Materials offerings include polyether polyols, urethane prepolymers, and comprehensive urethane systems. For Functional Materials, DKS manufactures radiation-curable monomers and oligomers, waterborne polyurethanes, flame retardants, and amide-based lubricants. The Electronic Device Materials group supplies ionic liquids, ion-conductive polymers, ceramic/metal injection molding components, conductive pastes for electronic applications, injection molding pellets, and advanced inorganic materials. Furthermore, the Life Sciences segment crafts health and dietary supplements, notably an I. Japonica-Bombyx Fungus product and Sudachin, a distinct citrus peel extract powder. Founded in 1909, the firm was formerly known as Dai-ichi Kogyo Seiyaku Co., Ltd. before rebranding to DKS Co. Ltd. in 2013.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||